Next presentation this afternoon is from DexCom, a leader in developing and commercializing continuous glucose monitoring systems for people with diabetes and I'm sure in the future beyond diabetes.
Dexcom faces mounting scrutiny over G7 safety concerns, FDA violations, financial practices, and growing competition from ...
DexCom (DXCM) stock declines after a short report, yet analysts from TD Cowen and Baird stay bullish on the company's ...
At the 61st annual European Association for the Study of Diabetes Conference (EASD) this week in Vienna, Austria, glucose monitoring company Dexcom introduced its new offering, the Dexcom Smart Basal, ...
Investing.com - UBS maintained its Buy rating and $106.00 price target on DexCom (NASDAQ:DXCM) following a Friday sell-off triggered by concerns about the company’s G7 continuous glucose monitoring ...
The device, called Biolinq Shine, is indicated for people with Type 2 diabetes who don’t depend on insulin. Biolinq says its ...
StockStory.org on MSN
Why DexCom (DXCM) Shares Are Trading Lower Today
Shares of medical device company DexCom (NASDAQ:DXCM) fell 7.4% in the morning session after a short-seller report from ...
Of the 100 largest medical device companies, these 10 firms have spent the largest portion of their revenues on research and ...
The Costco advantage doesn't just extend to your favorite grocery items and low-priced Interstate batteries. The warehouse retail chain also offers wholesale prices for tires, and they're a fantastic ...
The FDA identified a recall of smartphone apps for Dexcom (Nasdaq:DXCM) continuous glucose monitors as the most serious type.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback